A Phase II study of intravenous 6-thioguanine (NSC-752) in advanced colorectal carcinoma

J. Rubin, A. J. Schutt, H. C. Pitot IV

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Fifteen patients with advanced measurable colorectal carcinoma were treated with intravenous 6-thioguanine (6-TG) at a dosage of 55 mg/m2 for 5 consecutive days every 5 weeks. Only one patient had received prior adjuvant chemotherapy. No responses were detected, and eight patients had stable disease for a median duration of three treatment cycles. Toxicity was tolerable. We conclude that 6-TG given by this dosage schedule is ineffective in treating metastatic colorectal carcinoma.

Original languageEnglish (US)
Pages (from-to)236-238
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume15
Issue number3
DOIs
StatePublished - Jan 1 1992

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A Phase II study of intravenous 6-thioguanine (NSC-752) in advanced colorectal carcinoma'. Together they form a unique fingerprint.

  • Cite this